The Visceral Leishmaniasis Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Visceral Leishmaniasis Market?
The market size of the visceral leishmaniasis has experienced robust growth in previous years. This market was valued at $1.00 billion in 2024 and projected to reach $1.06 billion by 2025, expanding at a compound annual growth rate (CAGR) of 6.1%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Visceral Leishmaniasis Industry?
The global market for Visceral Leishmaniasis is projected to grow to a value of $1.33 billion in 2029, with a compound annual growth rate (CAGR) of 5.8%.
Download Your Free Sample of the 2025 Visceral Leishmaniasis Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Visceral Leishmaniasis Market?
The key drivers in the Visceral Leishmaniasis market are:
• Increasing investments in the development of vaccines for visceral leishmaniasis
• Enhancement of global disease surveillance programs
• Rise in public-private collaborations focused on visceral leishmaniasis treatment and prevention
• Improved funding for neglected tropical diseases and development of gene-based therapies
Global Market Segmentation: Identifying Major Visceral Leishmaniasis Industry Segments
The visceral leishmaniasis market covered in this report is segmented –
1) By Treatment: Antiparasitic, Antifungal, Other Treatments
2) By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods
3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Pre-order the 2025 Visceral Leishmaniasis Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Visceral Leishmaniasis Market?
The key trends in the Visceral Leishmaniasis market are:
• The market is experiencing a growing focus on the development of vaccines and gene-based therapies for visceral leishmaniasis.
• Advances in technology, such as CRISPR-based gene editing, AI-driven drug discovery, and nanotechnology-enhanced drug delivery, are increasingly prevalent.
• The use of next-generation sequencing for parasite analysis, wearable biosensors for early detection, and blockchain for medical supply chain management are emerging trends.
• There is an increasing use of smartphone-based diagnostic tools and 3D bioprinting for personalized treatment research in the market.
Who Are the Top Competitors & Leading Players in the Visceral Leishmaniasis Market?
Major companies in the Visceral Leishmaniasis market are:
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Novartis AG
• GSK plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories
• Aurobindo Pharma Limited
• Cipla Limited
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Limited
• Alkem Laboratories Ltd
• Xellia Pharmaceuticals
• Knight Therapeutics Inc
• Gufic Biosciences Ltd.
• United Biotech Private Limited
• DNDi
• TLC
Regional Dominance: Which Area Leads the Global Visceral Leishmaniasis Market?
North America was the largest region in the visceral leishmaniasis market in 2024
